OPEN ACCESS

REVIEW

Cornelia de Lange syndrome: from molecular diagnosis to therapeutic approach

Patrizia Sarogni, Maria M Pallotta, Antonio Musio

Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Pisa, Italy

Correspondence to

Dr Antonio Musio, Istituto di Ricerca Genetica e Biomedica, Pisa 56124, Italy; antonio.musio@irgb.cnr.it

PS and MMP are joint first authors.

Received 8 May 2019

Revised 8 August 2019

Accepted 2 October 2019

Published Online First 8

November 2019

ABSTRACT

Cornelia de Lange syndrome (CdLS) is a severe genetic disorder characterised by multisystemic malformations. CdLS is due to pathogenetic variants in *NIPBL*, *SMC1A*, *SMC3*, *RAD21* and *HDAC8* genes which belong to the cohesin pathway. Cohesin plays a pivotal role in chromatid cohesion, gene expression, and DNA repair. In this review, we will discuss how perturbations in those biological processes contribute to CdLS phenotype and will emphasise the state-of-art of CdLS therapeutic approaches.

INTRODUCTION

The cohesin complex, composed of four core subunits, SMC1A, SMC3, RAD21 and STAG, forms a ring-shaped structure that encircles chromatin.¹ It is evolutionarily conserved from prokaryotic to eukaryotic organisms. Additional factors, such as NIPBL, PDS5, WAPL, HDAC8 and ESCO, finely regulate the activity of cohesin during the cell cycle (figure 1). Cohesin loading onto chromatin is mediated from NIPBL, in association with its molecular partner MAU2.^{2,3} It occurs in G1 in yeast or at the end of telophase of the previous cell cycle in mammalian cells. ESCO proteins (1 and 2) allow cohesin establishment in the S phase, and PDS5 (A and B) guarantees its maintenance.^{4–7} WAPL contributes to cohesin dissolution and HDAC8 is necessary for cohesin recycling during the cell

cycle.^{8,9} Though cohesin was first identified for its role in establishing sister chromatid cohesion, which is important for proper chromosome segregation, cohesin is a key regulator in gene expression^{10–12} and 3D genome organisation.^{13,14} In fact, cohesin cooperates with the sequence-specific DNA binding protein CTCF to organise the mammalian genome into structural topologically associated domains (TADs), chromatin loops and contact domains.^{15–19} It is thought that these features compartmentalise genes and bring together distant enhancers with promoter sequences to orchestrate gene expression.^{20–22} The disruption of TADs and the removal of cohesin or CTCF binding sites result in abnormal DNA domain topology, thus leading to gene expression dysregulation.^{14,23–25} Cohesin is also essential for genome integrity as it controls fork replication speed,^{26,27} promotes DNA repair by homologous recombination,^{28–32} safeguards telomere stability^{33,34} and recruits proteins involved in G2/M checkpoints.^{35,36} DNA damage response and gene transcription are intimately associated via cohesin. In fact, in presence of DNA double-strand breaks, cohesin represses transcription in the flanking chromatin.^{37,38} Because of this role, it is not surprising that cohesin's pathogenetic variants are frequently found in cancer, including colorectal and urothelial carcinomas, Ewing sarcomas and acute myeloid leukaemia.^{39–45}

Cohesin and Cornelia de Lange syndrome

The finding that germinal pathogenetic variants in cohesin structural and regulatory genes are associated with human diseases collectively called 'cohesinopathies' may be less counterintuitive. Cornelia de Lange syndrome (CdLS; OMIM 122470, 300590, 610759, 614701, 300882) is the most frequently represented among these. CdLS is a rare multiorgan development disease with a prevalence ranging from 1:10 000 to 1:30 000 live births without differences between ethnic groups.⁴⁶ Its clinical presentation is characterised by facial dysmorphism (arched eyebrows with synophrys, long philtrum, thin lips, hirsute forehead), prenatal and postnatal growth retardation, cognitive impairment ranging from mild to severe, gastrointestinal malformations, congenital heart abnormalities and limb defects.⁴⁷ At present, five CdLS-causative genes have been identified. Pathogenetic variants in *NIPBL* account for about 60% of patients with CdLS whereas about 5%–10% of CdLS probands carry pathogenetic variants in *SMC1A*, *SMC3*, *RAD21* or *HDAC8*.^{9,48–52} This observation suggests that other genes responsible for CdLS have to be identified.

Figure 1 Cohesin and cell cycle. Cohesin is loaded onto chromosomes prior to DNA replication by a binary protein complex formed by NIPBL and MAU2. ESCO (1 and 2) are acetyltransferases that establish sister chromatid cohesion during DNA replication by promoting the acetylation of a pair of lysine residues within SMC3. Pds5 (A and B) has a cohesive effect on cohesin, while having the opposite impact when associated with Wap1. Finally, HDAC8, a histone deacetylase, targets SMC3 permitting cohesin recycling.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Sarogni P, Pallotta MM, Musio A. *J Med Genet* 2020;**57**:289–295.

Figure 2 Genotype–phenotype correlation in Cornelia de Lange syndrome. *NIPBL* truncating pathogenetic variants result in a more severe phenotype, whereas *HDAC8*, *NIPBL*, *RAD21*, *SMC1A* and *SMC3* missense mutations and in-frame deletions are associated with a milder phenotype.

Analysis of the mutational spectrum reveals a genotype–phenotype correlation (figure 2). *NIPBL* truncating, nonsense, splice site and frame shift pathogenetic variants leading to a truncated and likely non-functional *NIPBL* protein are associated with a severe phenotype. The clinical picture of patients with CdLS carrying *SMC1A*, *SMC3* and *RAD21* pathogenetic variants is more uniform, characterised by a mild to moderate phenotype more similar to *NIPBL*-mutated probands who carry missense changes. Finally, patients harbouring pathogenetic variants in *HDAC8* gene show clinical traits overlapping to some extent with classic forms of CdLS characterised by typical facial dysmorphism and severe cognitive delay.⁵³

The molecular diagnosis of CdLS is complicated by both the presence of somatic mosaicism and the overlap with other diseases. In fact, sequencing of DNA extracted from fibroblasts or buccal mucosa allowed the identification of mosaic variants in all five CdLS genes in patients originally reported to be mutation negative by Sanger sequencing on DNA isolated from blood.^{54–58} In order to provide an accurate diagnosis, these variants are of particular interest since they may escape routine molecular diagnostics and indicate that sequencing should not be restricted to DNA from blood samples. Furthermore, patients presenting CdLS or CdLS-like phenotype have been described, and interestingly they carried pathogenetic variants in chromatin-associated factors (table 1) such as *BRD4* and *AFF4* (responsible for CHOPS syndrome, OMIM 616368); *ANKRD11* (associated with KBG syndrome, OMIM 148050); *EP300* (responsible for Rubinstein-Taybi syndrome (RSTS), OMIM 613684) and *KMT2A* (causal gene for Wiedemann-Steiner syndrome (WDSTS), OMIM 605130); and *ARID1B*, *ARID1A*, *SMARCB1*, *SMARCA4*, *SMARCE1*, *ARID2*, *SOX11* and *DPF2* (associated with Coffin-Siris syndrome (CSS), OMIM 614556, 603024, 601607, 603254, 603111, 609539, 600898, 601671).^{59–71} Interestingly, all of these disorders display a significant clinical overlap with CdLS, each presenting with shared features that embrace facial dysmorphism, intellectual disability, growth and developmental delay and that are regularly considered in the differential diagnosis of CdLS. These findings suggest that the clinical overlap of these syndromes is mirrored by molecular interactions belonging to the same path, and chromatin dysregulation is a common step towards the pathogenesis of developmental disorders that share phenotypical features with CdLS.

Table 1 Human diseases overlapping Cornelia de Lange syndrome (CdLS)

Disease	Gene(s)	Role
CdLS-like	BRD4	It binds to hyperacetylated genomic regions that encompass promoters and enhancers; regulates transcription elongation by paused RNA polymerase II ¹¹⁴
CHOPS	AFF4	It is a scaffold protein comprising the core component of the super elongation complex ⁸²
CSS	ARID1B, ARID1A, ARID2, DPF2, SMARCB1, SMARCA4, SMARCE1, SOX11	They are subunits of the ATP-dependent SWI/SNF (SWITCH/sucrose non-fermentable) chromatin remodelling complex involved in transcription ¹¹⁵
KBG	ANKRD11	It is associated with transcription through chromatin modification ¹¹⁶
RSTS	EP300	It functions as histone acetyltransferase that regulates transcription via chromatin remodelling ¹¹⁷
WDSTS	KMT2A	It is a histone methyltransferase that regulates chromatin-mediated transcription ¹¹⁸

Biological processes dysregulated in CdLS

Sister chromatid cohesion is not affected in CdLS^{72–73}; thus, the molecular mechanisms underlying CdLS remain elusive. Several dysregulated biological pathways have been documented in CdLS, including gene transcription, RNA biogenesis, DNA repair and oxidative stress response (figure 3).^{72–78} The cohesin complex, in association with its loader *NIPBL* and the insulator protein CTCF, regulates enhancer–promoter interaction and is responsible for creating the TADs.^{18–20–79} Genome-wide data show that cohesin binds more frequently to promoter and downstream regions and is associated with active gene in patients with CdLS.^{74–75} In addition, CdLS cells harbouring *SMC1A* pathogenetic variants or the partial decrease in *NIPBL* expression caused a distinctive profile of gene expression changes.^{74–75}

For this reason, CdLS is now grouped in a growing broader class of neurodevelopmental diseases, called disorders of transcriptional regulation (DTRs).⁸⁰ In addition to CdLS, DTRs include genetic diseases resulting from mutations in gene coding proteins for the transcriptional machinery, histone modification and chromatin remodelling. For example, CSS is characterised by facial dysmorphism, developmental delay, cognitive impairment, absence of terminal phalanges and fifth fingernail hypoplasia.⁸¹ CSS is a disorder of chromatin remodelling. In fact, it is caused by mutations in genes belonging to the SWI/SNF chromatin remodeller complex.^{68–69} CHOPS syndrome is characterised by round faces and arched eyebrows, intellectual disability, heart defects and short stature.⁵⁹ CHOPS patients carry a mutation in *AFF4* gene that encodes a component of the super elongation complex.^{59–82} Therefore, CHOPS syndrome may be considered a disorder of transcriptional elongation. KBG syndrome is characterised by facial dysmorphism, macrodontia of the upper central incisor, skeletal defects and cognitive impairment.⁸³ KBG syndrome is caused by mutations in *ANKRD11* gene which regulates histone acetylation,⁸⁴ thus it is a disorder of histone modifications. Gene transcription regulation is a fundamental biological process involving many aspects of cell life such as the interaction between enhancer and promoter

Figure 3 Most of CdLS are caused by mutations in cohesin and cohesin-regulatory genes. These mutations cause alterations in many fundamental biological processes such as transcription, DNA repair and translation, leading to gene expression dysregulation, high levels of oxidative stress and genome instability. A few cases are instead due to mutations in genes coding transcription machinery members or involved in chromatin remodelling and histone modification, which in turn cause gene changes.

by chromatin loop, histone modification and the formation of transcription apparatus. The observation that the number of diseases belonging to DTRs is increasing over the years indicates that perturbations in transcription regulation cause multiple developmental syndromes. In addition to gaining insight into the pathogenetic basis of human disorders, the study of DTRs also contributes to dissecting the molecular mechanism of gene transcription regulation.

The findings that CdLS cells show gene expression dysregulation and no defects in sister chromatid cohesion reveal a dosage-sensitive functional hierarchy of cohesin. Mitotic functions appear to be the least dose sensitive, while gene regulation is more dose sensitive. This view is further supported by the findings that the depletion of cohesin or *Nipped-B* (homologue of human *NIPBL*) in *Drosophila* cells and *Nipbl* in mice affected gene expression but did not cause cohesion or chromosome segregation defects.^{85 86}

The notion that gene transcription is dysregulated in CdLS is further supported by studies in animal models.^{86–88} Up to 1000 genes have been found dysregulated, but interestingly their fold changes were modest^{74 75 86 87} suggesting that phenotypic consequences arise from multiple collective perturbations in gene expression. The mechanism leading to gene dysregulation in CdLS is still poorly understood. However, pieces of data may help us to set up the puzzle. In fact, though cohesin is preferentially associated with transcription site start, the number of cohesin sites on differentially expressed genes is significantly reduced in CdLS, whereas the reduction is moderate for the non-differentially expressed genes.⁷⁴ In addition, mutant cohesin displays an increased affinity for chromatin making the cohesin–DNA binding more stable and impairs PolII recruitment at the promoter regions of dysregulated genes.^{72 75} It is reasonable to deduce that cohesin mutations cause chromatin modification, leading to global transcription disturbance in CdLS.

Cohesin binds to the ribosomal DNA, plays a role in nucleolus organisation and facilitates protein translation.^{89 90} It has been shown that rRNA production and protein synthesis are decreased in a zebrafish model of CdLS.⁹¹ This finding suggests that cohesin has the potential to affect the functions of the nucleolus, and some of the transcriptional changes observed in CdLS may occur as a result of translational defects.

CdLS cells are characterised by genome instability, as evidenced by the presence of chromosomal rearrangements and aberrations such as translocations, deletions, gaps and breaks.^{48 49 72 92} In addition, cells are sensitive to genotoxic drugs such as aphidicolin and mytomicin C, and X-ray exposure,^{72 93} suggesting that CdLS cells have a reduced ability to tolerate DNA damage, likely as a result of reduced DNA repair capability. These data raise the possibility that mutant cohesin may contribute to DNA damage sensitivity by altering the dynamic association of cohesin with DNA, which in turn impairs the recruitment of proteins involved in DNA repair. Oxidative stress could provide a further contribution to the genome instability detected in CdLS. In fact, it is well known that high levels of oxidative stress promote genome instability, apoptosis and cell growth arrest.^{94–96} Of note, experimental evidence shows the downregulation of proteins involved in the response to oxidative stress and an increase in global oxidative stress in CdLS cell lines.⁷⁸

Therapeutic approaches in CdLS

The discoveries made in recent years regarding both the identification of CdLS-causative genes and the cellular and molecular characterisation of CdLS cells (figure 3) are the basis for attempting a therapeutic approach in CdLS.

As reported above, CdLS is associated with defects in ribosome biogenesis and translation.⁹¹ It has been shown that treatment with L-leucine improves rRNA production, protein synthesis and cell survival and partially rescues developmental defects (embryo length, cartilage formation, and head and eye size) in a zebrafish model of CdLS.⁹¹ L-Leucine treatment results in TOR (target of rapamycin) pathway activation through a mechanism that involves the activity of leucyl tRNA synthase and of GTP activating proteins.^{97 98} The TOR pathway controls cell proliferation, protein translation and ribosome biogenesis.^{99–101} Treatment with lithium chloride (LiCl) partially rescues neural development in *nipblb* knockdown zebrafish embryos and cell death in fibroblasts of patients with CdLS.¹⁰² Interestingly, LiCl promotes the activation of both Wnt-b-catenin and TOR signalling pathways.¹⁰³

CdLS is characterised by several phenotypic markers, including growth delay, short stature and delayed puberty.¹⁰⁴ Recently, a girl carrying a de novo splicing mutation in *NIPBL* gene was treated at 4.3 years of age with recombinant human growth hormone (r-hGH). The r-hGH treatment led to a height gain of 1.6 SD score over 8 years¹⁰⁵ suggesting that hormonal therapy may be effective for patients with CdLS with short stature.

The relationship between oxidative stress and genome instability in neurodegeneration and senescence is well established.^{106–108} Oxidative stress is induced by the accumulation of reactive oxygen species. Interestingly, an intriguing link between oxidative stress and TOR pathway has been described, in particular related to age-dependent cognitive decline, pathogenesis of Alzheimer disease and Down syndrome.^{109–111} Treatment with antioxidant drugs reduces both the level of oxidative stress and genome instability, leading to the extension of in vitro lifespan of CdLS cell lines. In addition, treatment ameliorates the phenotypic feature of zebrafish modelling of CdLS.⁹² Antioxidant drugs

protect the DNA from damage and prevent cell death, as shown in cerebellar cells using *N*-acetyl-cysteine.^{112,113} Altogether, these data indicate that antioxidant therapy could provide a means of improving specific phenotypic features of CdLS.

CONCLUSION

There is increasing evidence that CdLS is caused by a combination of factors, such as gene expression dysregulation, accumulation of cellular damage and cellular phenotype ageing, which collectively contribute to the CdLS phenotype. CdLS therapy is taking its first steps. Chemical or hormonal treatment represents a valuable attempt to identify potential therapeutic targets for future treatment of patients with CdLS, and hopefully clinical trials are now becoming closer.

Acknowledgements We acknowledge the financial support of Fondazione Pisa to AM.

Contributors PS and MMP wrote the paper. AM conceived the structure and content, wrote and revised the manuscript.

Funding This study was funded by Fondazione Pisa.

Disclaimer The funder had no involvement.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Antonio Musio <http://orcid.org/0000-0001-7701-6543>

REFERENCES

- Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. *Annu Rev Genet* 2009;43:525–58.
- Ciosk R, Shirayama M, Shevchenko A, Tanaka T, Toth A, Shevchenko A, Nasmyth K. Cohesin's binding to chromosomes depends on a separate complex consisting of Scc2 and Scc4 proteins. *Mol Cell* 2000;5:243–54.
- Haering CH, Farcas A-M, Arumugam P, Metson J, Nasmyth K. The cohesin ring concatenates sister DNA molecules. *Nature* 2008;454:297–301.
- Rolf Ben-Shahar T, Heeger S, Lehane C, East P, Flynn H, Skehel M, Uhlmann F. Eco1-dependent cohesin acetylation during establishment of sister chromatid cohesion. *Science* 2008;321:563–6.
- Unal E, Heidinger-Pauli JM, Kim W, Guacci V, Onn I, Gygi SP, Koshland DE. A molecular determinant for the establishment of sister chromatid cohesion. *Science* 2008;321:566–9.
- Panizza S, Tanaka T, Hochwagen A, Eisenhaber F, Nasmyth K. Pds5 cooperates with cohesin in maintaining sister chromatid cohesion. *Curr Biol* 2000;10:1557–64.
- Losada A, Yokochi T, Hirano T. Functional contribution of Pds5 to cohesin-mediated cohesion in human cells and *Xenopus* egg extracts. *J Cell Sci* 2005;118:2133–41.
- Tedeschi A, Wutz G, Huet S, Jaritz M, Wuensche A, Schirghuber E, Davidson IF, Tang W, Cisneros DA, Bhaskara V, Nishiyama T, Vaziri A, Wutz A, Ellenberg J, Peters J-M. Wapl is an essential regulator of chromatin structure and chromosome segregation. *Nature* 2013;501:564–8.
- Deardorff MA, Bando M, Nakato R, Watrin E, Itoh T, Minamino M, Saitoh K, Komata M, Katou Y, Clark D, Cole KE, De Baere E, Decroos C, Di Donato N, Ernst S, Francey L, Gytfordimou Y, Hirashima K, Hullings M, Ishikawa Y, Jaulin C, Kaur M, Kiyono T, Lombardi PM, Magnaghi-Jaulin L, Mortier GR, Nozaki N, Petersen MB, Seimiya H, Siu VM, Suzuki Y, Takagaki K, Wilde JJ, Willems PJ, Prigent C, Gillissen-Kaesbach G, Christianson DW, Kaiser FJ, Jackson LG, Hirota T, Krantz ID, Shirahige K. Hdac8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature* 2012;489:313–7.
- Huang J, Li K, Cai W, Liu X, Zhang Y, Orkin SH, Xu J, Yuan G-C. Dissecting super-enhancer hierarchy based on chromatin interactions. *Nat Commun* 2018;9:943.
- Dowen JM, Bilodeau S, Orlando DA, Hübner MR, Abraham BJ, Spector DL, Young RA. Multiple structural maintenance of chromosome complexes at transcriptional regulatory elements. *Stem Cell Reports* 2013;1:371–8.
- Cuartero S, Weiss FD, Dharmalingam G, Guo Y, Ing-Simmons E, Masella S, Robles-Rebollo I, Xiao X, Wang Y-F, Barozzi I, Djehoulou D, Amano MT, Niskanen H, Petretto E, Dowell RD, Tachibana K, Kaikkonen MU, Nasmyth KA, Lenhard B, Natoli G, Fisher AG, Merkenschlager M. Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation. *Nat Immunol* 2018;19:932–41.
- Rao SSP, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, Sanborn AL, Machol I, Omer AD, Lander ES, Aiden EL. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* 2014;159:1665–80.
- Schwarzer W, Abdennur N, Goloborodko A, Pekowska A, Fudenberg G, Loe-Mie Y, Fonseca NA, Huber W, Haering CH, Mirny L, Spitz F. Two independent modes of chromatin organization revealed by cohesin removal. *Nature* 2017;551:51–6.
- Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, Schirghuber E, Tsutsumi S, Nagae G, Ishihara K, Mishihiro T, Yahata K, Imamoto F, Aburatani H, Nakao M, Imamoto N, Maeshima K, Shirahige K, Peters J-M. Cohesin mediates transcriptional insulation by CCCTC-binding factor. *Nature* 2008;451:796–801.
- Rubio ED, Reiss DJ, Welch DJ, Distche CM, Filippova GN, Baliga NS, Aebersold R, Ranish JA, Krumm A. Ctf physically links cohesin to chromatin. *Proc Natl Acad Sci U S A* 2008;105:8309–14.
- Parelho V, Hadjir S, Spivakov M, Leleu M, Sauer S, Gregson HC, Jarmuz A, Canzonetta C, Webster Z, Nesterova T, Cobb BS, Yokomori K, Dillon N, Aragon L, Fisher AG, Merkenschlager M. Cohesins functionally associate with CTCF on mammalian chromosome arms. *Cell* 2008;132:422–33.
- Zuin J, Dixon JR, van der Reijden MIJA, Ye Z, Kolovos P, Brouwer RWW, van de Corput MPC, van de Werken HJG, Knoch TA, van Ijcken WJF, Grosveld FG, Ren B, Wendt KS. Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. *Proc Natl Acad Sci U S A* 2014;111:996–1001.
- Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier CC, Goossens J, Rahl PB, Levine SS, Taatjes DJ, Dekker J, Young RA. Mediator and cohesin connect gene expression and chromatin architecture. *Nature* 2010;467:430–5.
- Rao SSP, Huang S-C, Glenn St Hilaire B, Engreitz JM, Perez EM, Kieffer-Kwon K-R, Sanborn AL, Johnstone SE, Bascom GD, Bochkov ID, Huang X, Shamim MS, Shin J, Turner D, Ye Z, Omer AD, Robinson JT, Schlick T, Bernstein BE, Casellas R, Lander ES, Aiden EL. Cohesin loss eliminates all loop domains. *Cell* 2017;171:e24:305–20.
- Vian L, Pekowska A, Rao SSP, Kieffer-Kwon K-R, Jung S, Baranello L, Huang S-C, El Khattabi L, Dose M, Pruett N, Sanborn AL, Canela A, Maman Y, Oksanen A, Resch W, Li X, Lee B, Kovalchuk AL, Tang Z, Nelson S, Di Pierro M, Cheng RR, Machol I, St Hilaire BG, Durand NC, Shamim MS, Stamenova EK, Onuchic JN, Ruan Y, Nussenzweig A, Levins D, Aiden EL, Casellas R. The energetics and physiological impact of cohesin extrusion. *Cell* 2018;175:292–4.
- Haarhuis JHI, van der Weide RH, Blomen VA, Yáñez-Cuna JO, Amendola M, van Ruiten MS, Krijger PHL, Teunissen H, Medema RH, van Steensel B, Brummelkamp TR, de Wit E, Rowland BD. The cohesin release factor WAPL restricts chromatin loop extension. *Cell* 2017;169:e14:693–707.
- Hnisz D, Weintraub AS, Day DS, Valton A-L, Bak RO, Li CH, Goldmann J, Lajoie BR, Fan ZP, Sigova AA, Reddy J, Borges-Rivera D, Lee TI, Jaenisch R, Porteus MH, Dekker J, Young RA. Activation of proto-oncogenes by disruption of chromosome neighborhoods. *Science* 2016;351:1454–8.
- Seitan VC, Hao B, Tachibana-Konwalski K, Lavagnoli T, Mira-Bontenbal H, Brown KE, Teng G, Carroll T, Terry A, Horan K, Marks H, Adams DJ, Schatz DG, Aragon L, Fisher AG, Krangel MS, Nasmyth K, Merkenschlager M. A role for cohesin in T-cell-receptor rearrangement and thymocyte differentiation. *Nature* 2011;476:467–71.
- Narendra V, Rocha PP, An D, Raviram R, Skok JA, Mazzoni EO, Reinberg D. CTCF establishes discrete functional chromatin domains at the *Hox* clusters during differentiation. *Science* 2015;347:1017–21.
- Cucco F, Palumbo E, Camerini S, D'Alessio B, Quarantotti V, Casella ML, Rizzo IM, Cukrov D, Delia D, Russo A, Crescenzi M, Musio A. Separase prevents genomic instability by controlling replication fork speed. *Nucleic Acids Res* 2018;46:267–78.
- Terret M-E, Sherwood R, Rahman S, Qin J, Jallepalli PV. Cohesin acetylation speeds the replication fork. *Nature* 2009;462:231–4.
- Potts PR, Porteus MH, Yu H. Human SMC5/6 complex promotes sister chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to double-strand breaks. *EMBO J* 2006;25:3377–88.
- Gelot C, Guirouilh-Barbat J, Le Guen T, Dardillac E, Chailleux C, Canitrot Y, Lopez BS. The cohesin complex prevents the end joining of distant DNA double-strand ends. *Mol Cell* 2016;61:15–26.
- Schär P, Fäsi M, Jessberger R. SMC1 coordinates DNA double-strand break repair pathways. *Nucleic Acids Res* 2004;32:3921–9.
- Jessberger R, Podust V, Hübscher U, Berg P. A mammalian protein complex that repairs double-strand breaks and deletions by recombination. *J Biol Chem* 1993;268:15070–9.
- Jessberger R, Berg P. Repair of deletions and double-strand gaps by homologous recombination in a mammalian in vitro system. *Mol Cell Biol* 1991;11:445–57.
- Cipressa F, Morciano P, Bosso G, Mannini L, Galati A, Raffa GD, Caccione S, Musio A, Cenci G. A role for separase in telomere protection. *Nat Commun* 2016;7:10405.
- Daniloski Z, Smith S. Loss of tumor suppressor STAG2 promotes telomere recombination and extends the replicative lifespan of normal human cells. *Cancer Res* 2017;77:5530–42.

- 35 Watrin E, Peters J-M. The cohesin complex is required for the DNA damage-induced G2/M checkpoint in mammalian cells. *Embo J* 2009;28:2625–35.
- 36 Musio A, Montagna C, Mariani T, Tilenni M, Focarelli ML, Brait L, Indino E, Benedetti PA, Chessa L, Albertini A, Ried T, Vezzoni P. Smc1 involvement in fragile site expression. *Hum Mol Genet* 2005;14:525–33.
- 37 Meisenberg C, Pinder SI, Hopkins SR, Wooler SK, Benstead-Hume G, Pearl FMG, Jeggo PA, Downs JA. Repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. *Mol Cell* 2019;73:212–23.
- 38 Brownlee PM, Chambers AL, Cloney R, Bianchi A, Downs JA. BAF180 promotes cohesin and prevents genome instability and aneuploidy. *Cell Rep* 2014;6:973–81.
- 39 Kon A, Shih L-Y, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, Ishikawa S, Sato-Otsubo A, Nagae G, Nishimoto A, Haeflrich C, Nowak D, Sato Y, Alpermann T, Nagasaki M, Shimamura T, Tanaka H, Chiba K, Yamamoto R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Nakamaki T, Ishiyama K, Nolte F, Hofmann W-K, Miyawaki S, Chiba S, Mori H, Nakauchi H, Koeffler HP, Aburatani H, Haeflrich T, Shirahige K, Miyano S, Ogawa S. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nat Genet* 2013;45:1232–7.
- 40 Barber TD, McManus K, Yuen KKY, Reis M, Parmigiani G, Shen D, Barrett I, Nouhi Y, Spencer F, Markowitz S, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C, Hieter P. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. *Proc Natl Acad Sci U S A* 2008;105:3443–8.
- 41 Cucco F, Servadio A, Gatti V, Bianchi P, Mannini L, Prodromo A, De Vitis E, Basso G, Friuli A, Laghi L, Soddu S, Fontanini G, Musio A. Mutant cohesin drives chromosomal instability in early colorectal adenomas. *Hum Mol Genet* 2014;23:6773–8.
- 42 Solomon DA, Kim J-S, Bondaruk J, Shariat SF, Wang Z-F, Elkahlon AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PCW, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. *Nat Genet* 2013;45:1428–30.
- 43 Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahlon AG, Harris BT, Toretzky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim J-S, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. *Science* 2011;333:1039–43.
- 44 Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* 2014;505:495–501.
- 45 Sarogni P, Palumbo O, Servadio A, Astigiano S, D'Alessio B, Gatti V, Cukrov D, Baldari S, Pallotta MM, Aretini P, Dell'Orletta F, Soddu S, Carella M, Toietta G, Barbieri O, Fontanini G, Musio A. Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. *J Exp Clin Cancer Res* 2019;38.
- 46 Ramos FJ, Puisac B, Baquero-Montoya C, Gil-Rodríguez MC, Bueno I, Deardorff MA, Hennekam RC, Kaiser FJ, Krantz ID, Musio A, Selicorni A, FitzPatrick DR, Pié J. Clinical utility gene card for: Cornelia de Lange syndrome. *Eur J Hum Genet* 2015;23:1431.
- 47 Kline AD, Moss JF, Selicorni A, Bisgaard A-M, Deardorff MA, Gillett PM, Ishman SL, Kerr LM, Levin AV, Mulder PA, Ramos FJ, Wierzbicka J, Ajmone PF, Axtell D, Blagowidow N, Cereda A, Costantino A, Cormier-Daire V, FitzPatrick D, Grados M, Groves L, Guthrie W, Huisman S, Kaiser FJ, Koekkoek G, Levis M, Mariani M, McCleery JP, Menke LA, Metrena A, O'Connor J, Oliver C, Pie J, Piening S, Potter CJ, Quaglio AL, Redeker E, Richman D, Rigamonti C, Shi A, Tümer Z, Van Balkom IDC, Hennekam RC. Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement. *Nat Rev Genet* 2018;19:649–66.
- 48 Tonkin ET, Wang T-J, Ligo S, Bamshad MJ, Strachan T. Nipbl, encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in Cornelia de Lange syndrome. *Nat Genet* 2004;36:636–41.
- 49 Krantz ID, McCallum J, DeScipio C, Kaur M, Gillis LA, Yeager D, Jukofsky L, Wasserman N, Bottani A, Morris CA, Nowaczyk MJM, Toriello H, Bamshad MJ, Carey JC, Rappaport E, Kawauchi S, Lander AD, Calof AL, Li H-H, Devoto M, Jackson LG. Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. *Nat Genet* 2004;36:631–5.
- 50 Musio A, Selicorni A, Focarelli ML, Gervasini C, Milani D, Russo S, Vezzoni P, Larizza L. X-Linked Cornelia de Lange syndrome owing to SMC1L1 mutations. *Nat Genet* 2006;38:528–30.
- 51 Deardorff MA, Kaur M, Yeager D, Rampuria A, Korolev S, Pie J, Gil-Rodríguez C, Arnedo M, Loeys B, Kline AD, Wilson M, Lillquist K, Siu V, Ramos FJ, Musio A, Jackson LS, Dorsett D, Krantz ID. Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of Cornelia de Lange syndrome with predominant mental retardation. *Am J Hum Genet* 2007;80:485–94.
- 52 Deardorff MA, Wilde JJ, Albrecht M, Dickinson E, Tennstedt S, Braunholz D, Mönnich M, Yan Y, Xu W, Gil-Rodríguez MC, Clark D, Hakonarson H, Halbach S, Michels LD, Rampuria A, Rossier E, Spranger S, Van Maldergem L, Lynch SA, Gillessen-Kaesbach G, Lüdecke H-J, Ramsay RG, McKay MJ, Krantz ID, Xu H, Horsfield JA, Kaiser FJ. Rad21 mutations cause a human cohesinopathy. *Am J Hum Genet* 2012;90:1014–27.
- 53 Mannini L, Cucco F, Quarantotti V, Krantz ID, Musio A. Mutation spectrum and genotype–phenotype correlation in Cornelia de Lange syndrome. *Hum Mutat* 2013;34:1589–96.
- 54 Huisman SA, Redeker EJW, Maas SM, Mannens MM, Hennekam RCM. High rate of mosaicism in individuals with Cornelia de Lange syndrome. *J Med Genet* 2013;50:339–44.
- 55 Pozojevic J, Parenti I, Graul-Neumann L, Ruiz Gil S, Watrin E, Wendt KS, Werner R, Strom TM, Gillessen-Kaesbach G, Kaiser FJ. Novel mosaic variants in two patients with Cornelia de Lange syndrome. *Eur J Med Genet* 2018;61:680–4.
- 56 Slavin TP, Lazebnik N, Clark DM, Vengoechea J, Cohen L, Kaur M, Konczal L, Crowe CA, Corteville JE, Nowaczyk MJ, Byrne JL, Jackson LG, Krantz ID. Germline mosaicism in Cornelia de Lange syndrome. *Am J Med Genet A* 2012;158A:1481–5.
- 57 Ansari M, Poke G, Ferry Q, Williamson K, Aldridge R, Meynert AM, Bengani H, Chan CY, Kayserili H, Avci S, Hennekam RCM, Lampe AK, Redeker E, Homfray T, Ross A, Falkenberg Smeland M, Mansour S, Parker MJ, Cook JA, Splitt M, Fisher RB, Fryer A, Magee AC, Wilkie A, Barnicoat A, Brady AF, Cooper NS, Mercer C, Deshpande C, Bennett CP, Pilz DT, Ruddy D, Cilliers D, Johnson DS, Josifova D, Rosser E, Thompson EM, Wakeling E, Kinning E, Stewart F, Flinter F, Girisha KM, Cox H, Fifth HV, Kingston H, Wee JS, Hurst JA, Clayton-Smith J, Tolmie J, Vogt J, Tatton-Brown K, Chandler K, Prescott K, Wilson L, Behnam M, McEntagart M, Davidson R, Lynch S-A, Sisodiya V, Mehta SG, McKee SA, Mohammed S, Holden S, Park S-M, Holder SE, Harrison V, McConnell V, Lam WK, Green AJ, Donnai D, Bitner-Glindzic M, Donnelly DE, Nellaker C, Taylor MS, FitzPatrick DR. Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism. *J Med Genet* 2014;51:659–68.
- 58 Baquero-Montoya C, Gil-Rodríguez MC, Braunholz D, Teresa-Rodrigo ME, Obieglo C, Gener B, Schwarzmayr T, Strom TM, Gómez-Puertas P, Puisac B, Gillessen-Kaesbach G, Musio A, Ramos FJ, Kaiser FJ, Pié J. Somatic mosaicism in a Cornelia de Lange syndrome patient with NIPBL mutation identified by different next generation sequencing approaches. *Clin Genet* 2014;86:595–7.
- 59 Izumi K, Nakato R, Zhang Z, Edmondson AC, Noon S, Dulik MC, Rajagopalan R, Venditti CP, Gripp K, Samanich J, Zackai EH, Deardorff MA, Clark D, Allen JL, Dorsett D, Misulovin Z, Komata M, Bando M, Kaur M, Katou Y, Shirahige K, Krantz ID. Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin. *Nat Genet* 2015;47:338–44.
- 60 Olley G, Ansari M, Bengani H, Grimes GR, Rhodes J, von Kriegsheim A, Blatnik A, Stewart FJ, Wakeling E, Carroll N, Ross A, Park S-M, Bickmore WA, Pradeepa MM, FitzPatrick DR, Deciphering Developmental Disorders Study. BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange-like syndrome. *Nat Genet* 2018;50:329–32.
- 61 Parenti I, Gervasini C, Pozojevic J, Graul-Neumann L, Azzollini J, Braunholz D, Watrin E, Wendt KS, Cereda A, Cittaro D, Gillessen-Kaesbach G, Lazarevic D, Mariani M, Russo S, Werner R, Krawitz P, Larizza L, Selicorni A, Kaiser FJ. Broadening of cohesinopathies: exome sequencing identifies mutations in ANKRD11 in two patients with Cornelia de Lange-overlapping phenotype. *Clin Genet* 2016;89:74–81.
- 62 Parenti I, Teresa-Rodrigo ME, Pozojevic J, Ruiz Gil S, Bader I, Braunholz D, Bramswig NC, Gervasini C, Larizza L, Pfeiffer L, Ozkinay F, Ramos F, Reiz B, Rittinger O, Strom TM, Watrin E, Wendt K, Wiczorek D, Wollnik B, Baquero-Montoya C, Pié J, Deardorff MA, Gillessen-Kaesbach G, Kaiser FJ. Mutations in chromatin regulators functionally link Cornelia de Lange syndrome and clinically overlapping phenotypes. *Hum Genet* 2017;136:307–20.
- 63 Tang H, Guo J, Linpeng S, Wu L. Next generation sequencing identified two novel mutations in NIPBL and a frame shift mutation in CREBBP in three Chinese children. *Orphanet J Rare Dis* 2019;14:45.
- 64 Woods SA, Robinson HB, Kohler LJ, Agamanolis D, Sterbenz G, Khalifa M. Exome sequencing identifies a novel ep300 frame shift mutation in a patient with features that overlap Cornelia de Lange syndrome. *Am J Med Genet A* 2014;164A:251–8.
- 65 Yuan B, Pehlivan D, Karaca E, Patel N, Charnig W-L, Gambin T, Gonzaga-Jauregui C, Sutton VR, Yesil G, Bozdogan ST, Tos T, Koparic A, Koparic E, Beck CR, Gu S, Aslan H, Yuregir OO, Al Rubeaan K, Alnaqeb D, Alshammari MJ, Bayram Y, Atik MM, Aydin H, Geckinli BB, Seven M, Ulucan H, Fenercioglu E, Ozen M, Jhangiani S, Muzny DM, Boerwinkle E, Tuysuz B, Alkuray F, Gibbs RA, Lupski JR. Global transcriptional disturbances underlie Cornelia de Lange syndrome and related phenotypes. *J Clin Invest* 2015;125:636–51.
- 66 Vasileiou G, Vergarajauregui S, Ende S, Popp B, Büttner C, Ekici AB, Gerard M, Bramswig NC, Albrecht B, Clayton-Smith J, Morton J, Tomkins S, Low K, Weber A, Wenzel M, Altmüller J, Li Y, Wollnik B, Hoganson G, Plona M-R, Cho MT, Thiel CT, Lüdecke H-J, Strom TM, Alpermann T, Wilkie AOM, Wiczorek D, Engel FB, Reis A, Deciphering Developmental Disorders Study. Mutations in the BAF-complex subunit DPF2 are associated with Coffin-Siris syndrome. *Am J Hum Genet* 2018;102:468–79.
- 67 Hoyer J, Ekici AB, Ende S, Popp B, Zweier C, Wiesener A, Wohlleber E, Dufke A, Rossier E, Petsch C, Zweier M, Göhring I, Zink AM, Rappold G, Schröck E, Wiczorek D, Riess O, Engels H, Rauch A, Reis A. Haploinsufficiency of ARID1B, a member of the SWI/SNF-A chromatin-remodeling complex, is a frequent cause of intellectual disability. *Am J Hum Genet* 2012;90:565–72.
- 68 Santen GWE, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EAJ, Hilhorst-Hofstee Y, Wessels MW, den Hollander NS, Ruivenkamp CAL, van Ommen G-JB, Breuning MH, den Dunnen JT, van Haeringen A, Kriek M.

- Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat Genet* 2012;44:379–80.
- 69 Tsurusaki Y, Okamoto N, Ohashi H, Koshi T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, Fukushima Y, Homma T, Kato M, Hiraki Y, Yamagata T, Yano S, Mizuno S, Sakazume S, Ishii T, Nagai T, Shiina M, Ogata K, Ohta T, Niikawa N, Miyatake S, Okada I, Mizuguchi T, Doi H, Saitsu H, Miyake N, Matsumoto N. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nat Genet* 2012;44:376–8.
 - 70 Hempel A, Pagnamenta AT, Blyth M, Mansour S, McConnell V, Kou I, Ikegawa S, Tsurusaki Y, Matsumoto N, Lo-Castro A, Plessis G, Albrecht B, Battaglia A, Taylor JC, Howard MF, Keays D, Sohal AS, Kühl SJ, Kini U, McNeill A, DDD Collaboration. Deletions and de novo mutations of *SOX11* are associated with a neurodevelopmental disorder with features of Coffin-Siris syndrome. *J Med Genet* 2016;53:152–62.
 - 71 Bramswig NC, Caluseriu O, Lüdecke H-J, Bolduc FV, Noel NCL, Wieland T, Surowy HM, Christen H-J, Engels H, Strom TM, Wieczorek D. Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype. *Hum Genet* 2017;136:297–305.
 - 72 Revenkova E, Focarelli ML, Susani L, Paulis M, Bassi MT, Mannini L, Frattini A, Delia D, Krantz I, Vezzoni P, Jessberger R, Musio A. Cornelia de Lange syndrome mutations in SMC1A or SMC3 affect binding to DNA. *Hum Mol Genet* 2009;18:418–27.
 - 73 Castronovo P, Gervasini C, Cereda A, Masciadri M, Milani D, Russo S, Selicorni A, Larizza L. Premature chromatid separation is not a useful diagnostic marker for Cornelia de Lange syndrome. *Chromosome Res* 2009;17:763–71.
 - 74 Liu J, Zhang Z, Bando M, Itoh T, Deardorff MA, Clark D, Kaur M, Tandy S, Kondoh T, Rappaport E, Spinner NB, Vega H, Jackson LG, Shirahige K, Krantz ID. Transcriptional dysregulation in NIPBL and cohesin mutant human cells. *PLoS Biol* 2009;7:e1000119.
 - 75 Mannini L, C Lamaze F, Cucco F, Amato C, Quarantotti V, Rizzo IM, Krantz ID, Bilodeau S, Musio A. Mutant cohesin affects RNA polymerase II regulation in Cornelia de Lange syndrome. *Sci Rep* 2015;5:16803.
 - 76 Yuen KC, Xu B, Krantz ID, Gerton JL. NIPBL controls RNA biogenesis to prevent activation of the stress kinase PKR. *Cell Rep* 2016;14:93–102.
 - 77 Mannini L, Menga S, Tonelli A, Zanotti S, Bassi MT, Magnani C, Musio A. SMC1A codon 496 mutations affect the cellular response to genotoxic treatments. *Am J Med Genet A* 2012;158A:224–8.
 - 78 Gimigliano A, Mannini L, Bianchi L, Puglia M, Deardorff MA, Menga S, Krantz ID, Musio A, Bini L. Proteomic profile identifies dysregulated pathways in Cornelia de Lange syndrome cells with distinct mutations in *SMC1A* and *SMC3* genes. *J Proteome Res* 2012;11:6111–23.
 - 79 Fudenberg G, Imakaev M, Lu C, Goloborodko A, Abdennur N, Mirny LA. Formation of chromosomal domains by loop extrusion. *Cell Rep* 2016;15:2038–49.
 - 80 Izumi K. Disorders of transcriptional regulation: an emerging category of multiple malformation syndromes. *Mol Syndromol* 2016;7:262–73.
 - 81 Vergano SS, Deardorff MA. Clinical features, diagnostic criteria, and management of Coffin-Siris syndrome. *Am J Med Genet C Semin Med Genet* 2014;166C:252–6.
 - 82 Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, Washburn MP, Conaway JW, Conaway RC, Shilatifard A. AFF4, a component of the ELLP-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. *Mol Cell* 2010;37:429–37.
 - 83 Sirmaci A, Spiliopoulos M, Brancati F, Powell E, Duman D, Abrams A, Bademci G, Agolini E, Guo S, Konuk B, Kavaz A, Blanton S, Digilio MC, Dallapiccola B, Young J, Zuchner S, Tekin M. Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. *Am J Hum Genet* 2011;89:289–94.
 - 84 Gallagher D, Voronova A, Zander MA, Cancino GI, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD. Ankrd11 is a chromatin regulator involved in autism that is essential for neural development. *Dev Cell* 2015;32:31–42.
 - 85 Schaaf CA, Misulovin Z, Zahota G, Siddiqui AM, Schwartz YB, Kahn TG, Pirrotta V, Gause M, Dorsett D. Regulation of the Drosophila enhancer of split and invected-engrailed gene complexes by sister chromatid cohesion proteins. *PLoS One* 2009;4:e6202.
 - 86 Kawauchi S, Calof AL, Santos R, Lopez-Burks ME, Young CM, Hoang MP, Chua A, Lao T, Lechner MS, Daniel JA, Nussenzeig A, Kitzes L, Yokomori K, Hallgrímsson B, Lander AD. Multiple organ system defects and transcriptional dysregulation in the Nipbl^{+/−} mouse, a model of Cornelia de Lange Syndrome. *PLoS Genet* 2009;5:e1000650.
 - 87 Muto A, Calof AL, Lander AD, Schilling TF. Multifactorial origins of heart and gut defects in nipbl-deficient zebrafish, a model of Cornelia de Lange syndrome. *PLoS Biol* 2011;9:e1001181.
 - 88 Wu Y, Gause M, Xu D, Misulovin Z, Schaaf CA, Mosarlar RC, Mannino E, Shannon M, Jones E, Shi M, Chen W-F, Katz OL, Sehgal A, Jongens TA, Krantz ID, Dorsett D. Drosophila Nipped-B mutants model Cornelia de Lange syndrome in growth and behavior. *PLoS Genet* 2015;11:e1005655.
 - 89 Tomson BN, D'Amours D, Adamson BS, Aragon L, Amon A. Ribosomal DNA transcription-dependent processes interfere with chromosome segregation. *Mol Cell Biol* 2006;26:6239–47.
 - 90 Bose T, Lee KK, Lu S, Xu B, Harris B, Slaughter B, Unruh J, Garrett A, McDowell W, Box A, Li H, Peak A, Ramachandran S, Seidel C, Gerton JL. Cohesin proteins promote ribosomal RNA production and protein translation in yeast and human cells. *PLoS Genet* 2012;8:e1002749.
 - 91 Xu B, Sowa N, Cardenas ME, Gerton JL. L-Leucine partially rescues translational and developmental defects associated with zebrafish models of Cornelia de Lange syndrome. *Hum Mol Genet* 2015;24:1540–55.
 - 92 Cukrov D, Newman TAC, Leask M, Leeke B, Sarogni P, Patimo A, Kline AD, Krantz ID, Horsfield JA, Musio A. Antioxidant treatment ameliorates phenotypic features of SMC1A-mutated Cornelia de Lange syndrome in vitro and in vivo. *Hum Mol Genet* 2018;27:3002–11.
 - 93 Vrouwe MG, Elghalbzouri-Maghrani E, Meijers M, Schouten P, Godthelp BC, Bhuiyan ZA, Redeker EJ, Mannens MM, Mullenders LHF, Pastink A, Darroudi F. Increased DNA damage sensitivity of Cornelia de Lange syndrome cells: evidence for impaired recombinational repair. *Hum Mol Genet* 2007;16:1478–87.
 - 94 Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov* 2013;12:931–47.
 - 95 Birch-Machin MA, Bowman A. Oxidative stress and ageing. *Br J Dermatol* 2016;175(Suppl 2):26–9.
 - 96 Chamorro Ángel, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. *Lancet Neurol* 2016;15:869–81.
 - 97 Bonfils G, Jaquenoud M, Bontron S, Ostrowicz C, Ungermann C, De Virgilio C. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. *Mol Cell* 2012;46:105–10.
 - 98 Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, Ha SH, Ryu SH, Kim S. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. *Cell* 2012;149:410–24.
 - 99 Schmelzle T, Hall MN. Tor, a central controller of cell growth. *Cell* 2000;103:253–62.
 - 100 Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell* 2005;123:569–80.
 - 101 Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Mol Cell Biol* 2004;24:200–16.
 - 102 Pistocchi A, Fazio G, Cereda A, Ferrari L, Bettini LR, Messina G, Cotelli F, Biondi A, Selicorni A, Massa V. Cornelia de Lange syndrome: NIPBL haploinsufficiency downregulates canonical Wnt pathway in zebrafish embryos and patients fibroblasts. *Cell Death Dis* 2013;4:e866.
 - 103 Huang J, Nguyen-McCarty M, Hexner EO, Danet-Desnoyers G, Klein PS. Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. *Nat Med* 2012;18:1778–85.
 - 104 Kline AD, Grados M, Sponseller P, Levy HP, Blagowidow N, Schoedel C, Rampolla J, Clemens DK, Krantz I, Kimball A, Pichard C, Tuchman D. Natural history of aging in Cornelia de Lange syndrome. *Am J Med Genet C Semin Med Genet* 2007;145C:248–60.
 - 105 de Graaf M, Kant SG, Wit JM, Willem Redeker EJ, Eduard Santen GW, Henriëtte Verkerk AJM, Uitterlinden AG, Losekoot M, Oostdijk W. Successful growth hormone therapy in Cornelia de Lange syndrome. *J Clin Res Pediatr Endocrinol* 2017;9:366–70.
 - 106 Lee Y, McKinnon PJ. Responding to DNA double strand breaks in the nervous system. *Neuroscience* 2007;145:1365–74.
 - 107 Falcone G, Mazzola A, Michelini F, Bossi G, Censi F, Biferi MG, Minghetti L, Florida G, Federico M, Musio A, Crescenzi M. Cytogenetic analysis of human cells reveals specific patterns of DNA damage in replicative and oncogene-induced senescence. *Aging Cell* 2013;12:312–5.
 - 108 d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. *Nat Rev Cancer* 2008;8:512–22.
 - 109 Butterfield DA, Di Domenico F, Swomley AM, Head E, Perluigi M. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. *Biochem J* 2014;463:177–89.
 - 110 Di Domenico F, Barone E, Perluigi M, Butterfield DA. The triangle of death in Alzheimer's disease brain: the aberrant cross-talk among energy metabolism, mammalian target of rapamycin signaling, and protein homeostasis revealed by redox proteomics. *Antioxid Redox Signal* 2017;26:364–87.
 - 111 Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. *Biochim Biophys Acta* 2014;1842:1693–706.
 - 112 Reliene R, Fischer E, Schiessler RH. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in Atm-deficient mice. *Cancer Res* 2004;64:5148–53.
 - 113 Arakawa M, Ushimaru N, Osada N, Oda T, Ishige K, Ito Y. N-Acetylcysteine selectively protects cerebellar granule cells from 4-hydroxynonenal-induced cell death. *Neurosci Res* 2006;55:255–63.
 - 114 Kanno T, Kanno Y, LeRoy G, Campos E, Sun H-W, Brooks SR, Vahedi G, Heightman TD, Garcia BA, Reinberg D, Siebenlist U, O'Shea JJ, Ozato K. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. *Nat Struct Mol Biol* 2014;21:1047–57.

- 115 Sokpor G, Xie Y, Rosenbusch J, Tuoc T. Chromatin remodeling BAF (SWI/SNF) complexes in neural development and disorders. *Front Mol Neurosci* 2017;10:243.
- 116 Zhang A, Yeung PL, Li C-W, Tsai S-C, Dinh GK, Wu X, Li H, Chen JD. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. *J Biol Chem* 2004;279:33799–805.
- 117 Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, Loh Y-H, Yeo HC, Yeo ZX, Narang V, Govindarajan KR, Leong B, Shahab A, Ruan Y, Bourque G, Sung W-K, Clarke ND, Wei C-L, Ng H-H. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* 2008;133:1106–17.
- 118 Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R, Dubois G, Mazo A, Croce CM, Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. *Mol Cell* 2002;10:1119–28.